studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 793A
could potentially select F0–2 treatment-naïve G4 patients suitable
to shorten SMV+PR therapy to 12 weeks.
Disclosures:
Tarik Asselah - Consulting: Jannsen, AbbVie, Achillion, BMS, Gilead, Merck,
Roche; Speaking and Teaching: Jannsen, AbbVie, Achillion, BMS, Gilead,
Merck, Roche
Christophe Moreno - Consulting: Abbvie, Janssen, Gilead, BMS; Grant/Research
Support: Janssen, Gilead, Roche, Astellas
Christoph Sarrazin - Advisory Committees or Review Panels: Bristol-Myers
Squibb, Janssen, Merck/MSD, Gilead, Roche, Abbvie, Janssen, Merck/MSD;
Consulting: Merck/MSD, Merck/MSD; Grant/Research Support: Abbott, Roche,
Merck/MSD, Gilead, Janssen, Abbott, Roche, Merck/MSD, Qiagen; Speaking
and Teaching: Gilead, Novartis, Abbott, Roche, Merck/MSD, Janssen, Siemens,
Falk, Abbvie, Bristol-Myers Squibb, Achillion, Abbott, Roche, Merck/MSD, Janssen
Michael Gschwantler - Advisory Committees or Review Panels: Janssen, BMS,
Gilead, AbbVie; Speaking and Teaching: Janssen, BMS, Gilead, AbbVie
Graham R. Foster - Advisory Committees or Review Panels: GlaxoSmithKline,
Novartis, Boehringer Ingelheim, Tibotec, Chughai, Gilead, Janssen, Idenix,
GlaxoSmithKline, Novartis, Roche, Tibotec, Chughai, Gilead, Merck, Janssen,
Idenix, BMS; Board Membership: Boehringer Ingelheim; Grant/Research Support:
Chughai, Roche, Chughai; Speaking and Teaching: Roche, Gilead, Tibotec,
Merck, BMS, Boehringer Ingelheim, Gilead, Janssen
Peter Buggisch - Advisory Committees or Review Panels: Janssen, AbbVie, BMS;
Speaking and Teaching: Roche, MSD, Gilead, Merz Pharma
Faisal M. Sanai - Advisory Committees or Review Panels: Merck Sharpe Dohme,
Bristol Myers Squibb, Janssen Pharmaceuticals, Gilead Sciences; Grant/
Research Support: Roche Pharmaceuticals, Bristol Myers Squibb; Speaking and
Teaching: Roche Pharmaceuticals, Janssen Pharmaceuticals, Gilead Sciences,
Bayer Schering
Robert Ryan - Employment: Janssen Pharmaceuticals; Stock Shareholder: Janssen
Pharmaceutical
Oliver Lenz - Employment: Janssen; Stock Shareholder: Janssen (J&J)
Gino Van Dooren - Stock Shareholder: Johnson and Johnson
Isabelle Londjon-Domanec - Employment: Janssen
Catherine Nalpas - Employment: Janssen pharmaceuticals
Michael Schlag - Employment: Janssen Cilag Pharma; Stock Shareholder: Johnson
& Johnson
Maria Buti - Advisory Committees or Review Panels: Gilead, Janssen, MSD;
Grant/Research Support: Gilead, Janssen; Speaking and Teaching: Gilead,
Janssen, BMS
The following authors have nothing to disclose: Antonio Craxi
1180
Rapid drop in serum glucose and hypoglycemia in
chronic hepatitis C patients with diabetes during oral
HCV therapy
Laura M. Benítez-Gutiérrez 1 , Vincent Soriano 2 , Isabella Esposito 1 ,
Pablo Barreiro 2 , Ana Maria Duca 1 , Silvia Requena 1 , Isolina
Baños 1 , Ana Treviño 1 , Valentin Cuervas-Mons 1 , Carmen de Mendoza
1 ; 1 Internal Medicine, Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain; 2 Infectious Disease Unit,, La Paz
University Hospital & IdiPAZ, Madrid, Spain
Introduction: Chronic HCV infection is associated with metabolism
abnormalities, including insulin resistance. Up to 15-25%
of chronic hepatitis C patients will develop diabetes lifelong.
New DAA allow HCV suppression within a very short-time
frame. Little is known on the metabolic effects seen in chronic
hepatitis C patients on DAA. Methods: All chronic hepatitis C
patients that received sofosbuvir (SOF)-based regimens during
at least 4 weeks at two reference hepatitis clinics in Madrid
were retrospectively examined. Results: A total of 61 chronic
hepatitis C patients begun SOF-based regimens and had
weeks 0 and 4 controls. Regimens were as follows: SOF+simeprevir
(16), SOF+daclatasvir (13), SOF+ledipasvir (27) and
SOF+ribavirin (5). At 4 weeks 63% had undetectable viremia
and the rest had